Join the Hepatitis C group to help and get support from people like you.
Hepatitis C News
Related terms: Hepatitis C, Chronic, Chronic Hepatitis C, Hep C
More Than 460 CDC Workers Reinstated After Layoffs
FRIDAY, June 13, 2025 — More than 460 laid-off employees at the U.S. Centers for Disease Control and Prevention (CDC) are being rehired, officials said June 11. The reinstatement notices went out t...
U.S. FDA Approves Expanded Indication for AbbVie's Mavyret (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus
NORTH CHICAGO, Ill., June 11, 2025 /PRNewswire/ – AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved a label expansion for Mavyret (...
Jail Time Increases A Person's Risk of Death
THURSDAY, June 5, 2025 — Jail time has a huge effect on both an individual’s and a community’s long-term health, even after their release, a new study says. People serving time are 39% more likely to ...
Disparities Identified in Linkage to Care for Children With Hepatitis C
MONDAY, April 28, 2025 – Primary hepatitis C virus (HCV) care cascade outcomes are low among children with HCV, with racial and ethnic disparities identified in care access, according to a study...
Cancer Rates Are Falling in Appalachia, But Not Enough
MONDAY, Feb. 10, 2025 – Appalachia has a rich history and gorgeous landscapes, but it has also experienced rates of cancer incidence and death that outstrip those of much of the rest of America....
High Rates of Hep C Seen for Patients Presenting to ED With Opioid Overdose
WEDNESDAY, Nov. 13, 2024 – Patients presenting to emergency departments with opioid overdose have high rates of hepatitis C virus (HCV) infection, according to a study recently published in Cureus....
Model Can Predict, Stratify Liver Cancer Risk in Noncirrhotic Chronic Hep B
TUESDAY, Sept. 17, 2024 – A new prognostic model can predict and stratify hepatocellular carcinoma (HCC) risk in noncirrhotic adult patients with chronic hepatitis B (CHB), according to a study...
Liver Grafts Feasible From Hep C-Positive Donors After Circulatory Death
WEDNESDAY, Sept. 4, 2024 – Liver grafts from hepatitis C virus-positive (HCV+) donation after circulatory death (DCD) donors have one-year patient and graft survival comparable with that of donation...
Hep C Reinfection Observed in HIV-Positive Men Who Have Sex With Men
THURSDAY, Aug. 8, 2024 – The incidence rate of hepatitis C virus (HCV) reinfection was 4.7 per 100 person-years among men who have sex with men (MSM) with HIV who cleared HCV, according to a study...
Thousands of Hospital Patients in Oregon May Have Been Exposed to Hepatitis, HIV
FRIDAY, July 12, 2024 – After an anesthesiologist may have exposed thousands of people treated at several hospitals in Oregon to hepatitis and HIV, those patients are being advised to get tested for...
U.S. Food and Drug Administration Approves New Formulation of Epclusa, Expanding Pediatric Indication to Treat Children Ages 3 and Older With Chronic Hepatitis C
FOSTER CITY, Calif.--(BUSINESS WIRE)--Jun. 10, 2021-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today that the U.S. Food and Drug Administration (FDA) has approved an expansion of the pediatric...
FDA Approves Epclusa (sofosbuvir/velpatasvir) for Children Ages 6 and Older or Weighing at Least 17 kg with Chronic Hepatitis C Infection
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for...
FDA Approves Mavyret (glecaprevir/pibrentasvir) Treatment Duration of Eight Weeks for Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis Across All Genotypes
NORTH CHICAGO, Ill., Sept. 26, 2019 /PRNewswire/ – AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has...
FDA Medwatch Alert: FDA Warns About Rare Occurrence of Serious Liver Injury with Use of Hepatitis C Medicines Mavyret, Zepatier, and Vosevi in Some Patients with Advanced Liver Disease
August 28, 2019 – The Food and Drug Administration (FDA) has received reports that the use of Mavyret, Zepatier, or Vosevi to treat chronic hepatitis C in patients with moderate to severe liver...
FDA Approves Mavyret (glecaprevir and pibrentasvir) as First Treatment for All Genotypes of Hepatitis C in Pediatric Patients
April 30, 2019 -- The U.S. Food and Drug Administration today approved Mavyret (glecaprevir and pibrentasvir) tablets to treat all six genotypes of hepatitis C virus (HCV) in children ages 12 to 17. ...